NCT04361370View on ClinicalTrials.gov

Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

May 31, 2026

Study Completion Date

August 31, 2026

Conditions

Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer

Interventions

DRUG

Olaparib-Pembrolizumab-Bevacizumab

"* Olaparib 300mg (twice daily \[BID\])~* Pembrolizumab 200mg every 3 weeks (Q3W) from 2nd infusion for up to 35 infusions~* Bevacizumab 15mg/kg or 7.5mg/kg every 3 weeks (Q3W)"

Trial Locations (1)

Unknown

Yonsei Severance Hospital, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER